Complete histological regression of metastatic carcinoid tumour after treatment with octreotide

被引:31
|
作者
Imtiaz, KE [1 ]
Monteith, P [1 ]
Khaleeli, A [1 ]
机构
[1] Halton Gen Hosp, Dept Endocrinol, Runcorn, Cheshire, England
关键词
D O I
10.1046/j.1365-2265.2000.01126.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 69-year-old woman was admitted with facial flushing, weight loss and intermittent diarrhoea, Urinary 5-hydroxyindole-acetic acid (5-HIAA) level was elevated at 200 mu mol/24h (normal: <50), Computerized tomography (CT) demonstrated multiple enhancing liver metastases with biopsy proven carcinoid metastases with no evidence of primary tumour at this stage. Octreotide was initiated, resulting in marked improvement in carcinoid symptoms, Nine years later, she presented with abdominal pain and slightly deranged liver function tests, Repeat colonoscopy at this stage, showed an ileal tumour causing Impending obstruction, necessitating urgent right hemicolectomy. Histology demonstrated primary carcinoid tumour. She continued on octreotide. Three years later at the age of 81 years, she suffered a fatal haemorrhagic stroke. Autopsy revealed complete regression of hepatic carcinoid metastases.
引用
收藏
页码:755 / 758
页数:4
相关论文
共 50 条
  • [1] Treatment of metastatic carcinoid tumours with octreotide
    Özbey, N
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, 56 (05) : 407 - 407
  • [2] Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment
    Pregun, Istvan
    Gergics, Peter
    Dabasi, Gabriella
    Igaz, Peter
    Racz, Karoly
    Tulassay, Zsolt
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2009, 21 (04) : 386 - 387
  • [3] Carcinoid tumour treatment with 111in octreotide
    Kostoglou-Athanassiou, I
    Pappas, A
    Mytakidis, N
    Liakos, V
    Kourkoulou, M
    Kaldrymidis, P
    PROCEEDINGS OF THE 12TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY, 2004, : 1499 - 1503
  • [4] Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan)
    Hillman, N
    Herranz, L
    Alvarez, C
    Olmos, MAM
    Márco, A
    Gómez-Pan, A
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1998, 106 (03) : 226 - 230
  • [5] Treatment with octreotide to suppress corticotropin secretion by a carcinoid tumour
    Tirovola, EB
    Malpas, JS
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2005, 98 (11) : 516 - 516
  • [6] Long-term octreotide treatment of metastatic carcinoid tumor
    Corleto, VD
    Angeletti, S
    Schillaci, O
    Marignani, M
    Caratozzolo, M
    Panzuto, F
    Annibale, B
    Delle Fave, G
    ANNALS OF ONCOLOGY, 2000, 11 (04) : 491 - 493
  • [7] Regression of metastatic carcinoid tumors with octreotide therapy: Two case reports and a review of the literature
    Leong, WL
    Pasieka, JL
    JOURNAL OF SURGICAL ONCOLOGY, 2002, 79 (03) : 180 - 187
  • [8] Regression of metastatic carcinoid tumor after valvular surgery for carcinoid heart disease
    Rayson, D
    Pitot, HC
    Kvols, LK
    CANCER, 1997, 79 (03) : 605 - 611
  • [9] METASTATIC OVARIAN CARCINOID TUMOUR
    HOLLALLEN, RT
    POSTGRADUATE MEDICAL JOURNAL, 1969, 45 (519) : 46 - +
  • [10] Carcinoid tumour metastatic to the choroid
    Hykin, PG
    Shields, JA
    Shields, CL
    DePotter, PV
    Kehrli, WH
    BRITISH JOURNAL OF OPHTHALMOLOGY, 1996, 80 (09) : 852 - 853